Evidence map›Paper›PMID 34131801›Full record

ArticleJournal of cancer research and clinical oncology2022

Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.

Zhenwen Chen, Fei Chai, Yanfeng Xi, Hongwei Zhang, Yirong Xu, Zhaoxia Zhang, Su Li, Xiaoai Tian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zhenwen Chen *Department of Pathology, Fenyang College of Shanxi Medical University, Fenyang, China. Chenzhenwen@sxmu.edu.cn.ORCID http://orcid.org/0000-0002-4292-2340
Fei Chai *Department of Pathology, Fenyang College of Shanxi Medical University, Fenyang, China.
Yanfeng XiDepartment of Pathology, Shanxi Tumor Hospital, Taiyuan, China.
Hongwei ZhangDepartment of Hematology, Shanxi Tumor Hospital, Taiyuan, China.
Yirong XuDepartment of Pathology, Fenyang College of Shanxi Medical University, Fenyang, China.
Zhaoxia ZhangDepartment of Pathology, Fenyang College of Shanxi Medical University, Fenyang, China.
Su LiDepartment of Pathology, Fenyang College of Shanxi Medical University, Fenyang, China.
Xiaoai TianDepartment of Pathology, Shanxi Fenyang Hospital, Fenyang, China.
Shanxi Medical University · CNShanxi Provincial Cancer Hospital · CNShanxi Fenyang Hospital · CN

Funding

Intramural Research Program of Fenyang College of Shanxi Medical University 2016D10Intramural Research Program of Fenyang College of Shanxi Medical University 2016D12Natural Science Foundation of Shanxi Province 201701D121165Natural Science Foundation of Shanxi Province (CN) 2012011038-4, 201801D121347
6 · The paper itself

Abstract

purposec-MYC plays an important role in regulating cellular growth and apoptosis, and it is aberrantly expressed in many human malignancies. Although c-MYC has been extensively investigated in Burkitt lymphoma and diffuse large B cell lymphoma, little has been reported in anaplastic large cell lymphoma (ALCL). The aim of this study was to investigate the expression and genetic alterations of c-MYC in primary systemic ALCL, characterize its clinicopathologic features and immunophenotypes, and discuss their implications in prognosis.

methodsTissue microarrays using samples from 85 ALCL patients were used to evaluate expression of c-MYC and anaplastic lymphoma kinase (ALK). c-MYC and ALK genetic alterations were detected using fluorescence in situ hybridization. The Kaplan-Meier and multivariate Cox regression methods were used for survival analysis.

resultsc-MYC was expressed in 24 of 85 samples (28.2%), and ALK was expressed in 54 (63.5%). c-MYC and ALK were co-expressed in 16 samples (18.8%). c-MYC expression and c-MYC and ALK co-expression increased with ALCL clinical stages and the International Prognostic Index (IPI) score (p < 0.05). Fifty of the samples (58.8%) had ALK rearrangement, and 18 (22.1%) had aneuploidy. c-MYC rearrangement was not detected, but aneuploidy was observed in 19 cases (22.4%). c-MYC aneuploidy was significantly different based on c-MYC expression and the IPI score (p < 0.05). c-MYC was a significant independent prognostic factor for progression-free survival and overall survival in patients with ALCL.

conclusionc-MYC protein expression and c-MYC aneuploidy could predict worse survival in patients with ALCL.

Indexed as

AdolescentAdultAgedAnaplastic Lymphoma KinaseAneuploidyChildFemaleHumansIn Situ Hybridization, FluorescenceLymphoma, Large-Cell, AnaplasticMaleMiddle AgedPrognosisProto-Oncogene Proteins c-mycSurvival AnalysisYoung AdultALK protein, humanAnaplastic Lymphoma KinaseMYC protein, humanProto-Oncogene Proteins c-mycAnaplastic large cell lymphomac-MYCFluorescence in situ hybridizationImmunohistochemistryPrognosis

Identifiers

PMID34131801
PMCPMC11801146
OpenAlexW3167521958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.